James E. Flynn - 30 Sep 2025 SCHEDULE 13G/A Report for Lomond Therapeutics Holdings, Inc. Common Stock

Filing Manager
James E. Flynn
Reporting Manager
Deerfield Mgmt, L.P.
Security
Lomond Therapeutics Holdings, Inc. Common Stock
Shares outstanding
32,208,433 shares
Disclosed Ownership
2,692,625 shares
Ownership
8.4%
Form type
SCHEDULE 13G/A
Filing time
13 Nov 2025, 16:28:14 UTC
Date of event
30 Sep 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"James E. Flynn disclosed 8.4% ownership in Lomond Therapeutics Holdings, Inc. Common Stock on 30 Sep 2025."

Quick Takeaways

  • James E. Flynn filed SCHEDULE 13G/A for Lomond Therapeutics Holdings, Inc. Common Stock.
  • Disclosed ownership: 8.4%.
  • Date of event: 30 Sep 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 13 Nov 2025, 16:28.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Deerfield Mgmt, L.P. 8.4% 2,692,625 0 2,692,625 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Management Company, L.P. 8.4% 2,692,625 0 2,692,625 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Partners, L.P. 8.4% 2,692,625 0 2,692,625 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
James E. Flynn 8.4% 2,692,625 0 2,692,625 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

Sponsored